Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab and Orelabrutinib in Refractory Immune-related Cytopenia
NCT07574073Phase 1Not yet recruiting
- Sponsor
- Qideng Pharmaceutical
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- IgG Antibodies, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of hlx01 and orelabrutinib in cytopenia, immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA), sponsored by Qideng Pharmaceutical. Primary endpoint: Median overall response rate at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
hlx01orelabrutinib
03
Conditions
cytopeniaimmune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07574073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574073.